A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 79, Issue 1, 2011, Pages 126-134

  Jia, Zengrong ^a,b   Lin, Ping ^a   Xiang, Yu ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Fenofibrate; Nanomatrix; Oral bioavailability; Polymethylacrylate; Silica

Indexed keywords

AEROSIL; EUDRAGIT; FENOFIBRATE; NANOMATERIAL; POLYMER; SILICON DIOXIDE; SURFACTANT;

ANIMAL EXPERIMENT; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; MALE; MICROEMULSION; NONHUMAN; PH; PHYSICAL CHEMISTRY; RAT; SCANNING ELECTRON MICROSCOPY; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; COLLOIDS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; EMULSIONS; EXCIPIENTS; FENOFIBRATE; HYDROGEN-ION CONCENTRATION; HYPOLIPIDEMIC AGENTS; INTESTINAL ABSORPTION; MALE; NANOPORES; PARTICLE SIZE; POLYMERS; POLYMETHACRYLIC ACIDS; POLYMETHYL METHACRYLATE; RATS; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SOLUBILITY; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

EID: 80052273359     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2011.05.009     Document Type: Article

References (44)

1. D.J. Hauss Oral lipid-based formulations Adv. Drug Deliv. Rev. 59 2007 667 676 (Pubitemid 47285409)
2. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing-oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644 (Pubitemid 47285408)
3. A.T. Serajuddin Salt formation to improve drug solubility Adv. Drug Deliv. Rev. 59 2007 603 616 (Pubitemid 47285406)
4. V.J. Stella, and K.W. Nti-Addae Prodrug strategies to overcome poor water solubility Adv. Drug Deliv. Rev. 59 2007 677 694 (Pubitemid 47285410)
5. A.T. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
6. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Deliv. Rev. 59 2007 645 666 (Pubitemid 47299263)
7. N. Blagden, M. de Matas, P.T. Gavan, and P. York Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates Adv. Drug Deliv. Rev. 59 2007 617 630 (Pubitemid 47285407)
8. R.H. Muller, and C.M. Keck Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170 (Pubitemid 39237077)
9. M.R. Gasco Lipid nanoparticles: perspectives and challenges Adv. Drug Deliv. Rev. 59 2007 377 378 (Pubitemid 47259229)
10. W. Mehnert, and K. Mader Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196 (Pubitemid 32324113)
11. H. Takeuchi, S. Nagira, H. Yamamoto, and Y. Kawashima Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method Int. J. Pharm. 293 2005 155 164 (Pubitemid 40381089)
12. H. Friedrich, B. Fussnegger, K. Kolter, and R. Bodmeier Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers Eur. J. Pharm. Biopharm. 62 2006 171 177 (Pubitemid 43143269)
13. S.K. Jain, A.M. Awasthi, N.K. Jain, and G.P. Agrawal Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization J. Controlled Release 107 2005 300 309 (Pubitemid 41316292)
14. M.K. Gupta, A. Vanwert, and R.H. Bogner Formation of physically stable amorphous drugs by milling with Neusilin J. Pharm. Sci. 92 2003 536 551 (Pubitemid 36258968)
15. S. Rojtanatanya, and T. Pongjanyakul Propranolol-magnesium aluminum silicate complex dispersions and particles: characterization and factors influencing drug release Int. J. Pharm. 383 2010 106 115
16. J. Lu, M. Liong, J.I. Zink, and F. Tamanoi Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs Small 3 2007 1341 1346 (Pubitemid 47245524)
17. R. Mellaerts, R. Mols, P. Kayaert, P. Annaert, J. Van Humbeeck, G. Van den Mooter, J.A. Martens, and P. Augustijns Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport Int. J. Pharm. 357 2008 169 179
18. R. Mellaerts, R. Mols, J.A. Jammaer, C.A. Aerts, P. Annaert, J. Van Humbeeck, G. Van den Mooter, P. Augustijns, and J.A. Martens Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica Eur. J. Pharm. Biopharm. 69 2008 223 230
19. H. Miura, M. Kanebako, H. Shirai, H. Nakao, T. Inagi, and K. Terada Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide Eur. J. Pharm. Biopharm. 76 2010 215 221
20. J. Dai, T. Nagai, X. Wang, T. Zhang, M. Meng, and Q. Zhang pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A Int. J. Pharm. 280 2004 229 240 (Pubitemid 38950919)
21. X.Q. Wang, J.D. Dai, Z. Chen, T. Zhang, G.M. Xia, T. Nagai, and Q. Zhang Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration J. Controlled Release 97 2004 421 429 (Pubitemid 38802944)
22. D.A. Miller, J.C. DiNunzio, W. Yang, J.W. McGinity, and R.O. Williams Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption Pharm. Res. 25 2008 1450 1459
23. C.S. Wu, X.Q. Wang, M. Meng, M.G. Li, H. Zhang, X. Zhang, J.C. Wang, T. Wu, W.H. Nie, and Q. Zhang Effects of pH-sensitive nanoparticles prepared with different polymers on the distribution, adhesion and transition of Rhodamine 6G in the gut of rats J. Microencapsul. 27 2010 5
24. P. Ratanabanangkoon, H. Guzman, O. Almarsson, D. Berkovitz, S. Tokarcyzk, A.B. Straughn, and H. Chen A high-throughput approach towards a novel formulation of fenofibrate in omega-3 oil Eur. J. Pharm. Sci. 33 2008 351 360
25. M. Vogt, K. Kunath, and J.B. Dressman Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations Eur. J. Pharm. Biopharm. 68 2008 283 288
26. D.R. Guay Update on fenofibrate Cardiovasc. Drug Rev. 20 2002 281 302 (Pubitemid 36105782)
27. D.R. Guay Micronized fenofibrate: a new fibric acid hypolipidemic agent Ann. Pharmacother. 33 1999 1083 1103 (Pubitemid 29489991)
28. K. Tziomalos, and V.G. Athyros Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review Int. J. Nanomed. 1 2006 129 147
29. S.R. Vippagunta, Z. Wang, S. Hornung, and S.L. Krill Factors affecting the formation of eutectic solid dispersions and their dissolution behavior J. Pharm. Sci. 96 2007 294 304 (Pubitemid 46363560)
30. Y. Chen, Y. Lu, J. Chen, J. Lai, J. Sun, F. Hu, and W. Wu Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt Int. J. Pharm. 376 2009 153 160
31. A.R. Patel, and P.R. Vavia Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate AAPS J. 9 2007 E344 352
32. P. Ratanabanangkoon, H. Guzman, O. Almarsson, D. Berkouitz, S. Tokarcyzk, A.B. Straughn, and H.M. Chen A high-throughput approach towards a novel formulation of fenofibrate in omega-3 oil Eur. J. Pharm. Sci. 33 2008 351 360
33. V.P. Sant, D. Smith, and J.C. Leroux Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization J. Controlled Release 97 2004 301 312 (Pubitemid 38759487)
34. G.P. Sanganwar, and R.B. Gupta Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide Int. J. Pharm. 360 2008 213 218
35. P. Buch, P. Langguth, M. Kataoka, and S. Yamashita IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system J. Pharm. Sci. 98 2009 2001 2009
36. A. Hanafy, H. Spahn-Langguth, G. Vergnault, P. Grenier, M. Tubic Grozdanis, T. Lenhardt, and P. Langguth Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug Adv. Drug Deliv. Rev. 59 2007 419 426 (Pubitemid 47260709)
37. S. Brunauer, P.H. Emmett, and E. Teller Adsorption of gases in multimolecular layers J. Am. Chem. Soc. 60 1938 309 319
38. E.P. Barrett, L.G. Joyner, and P.P. Halenda The determination of pore volume and area distributions in porous substances. 1. Computations from nitrogen isotherms J. Am. Chem. Soc. 73 1951 373 380
39. R. Vandecruys, J. Peeters, G. Verreck, and M.E. Brewster Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design Int. J. Pharm. 342 2007 168 175 (Pubitemid 47259339)
40. J.C. DiNunzio, D.A. Miller, W. Yang, J.W. McGinity, and R.O. Williams Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole Mol. Pharm. 5 2008 968 980
41. M. Maghsoodi Physicomechanical properties of naproxen-loaded microparticles prepared from Eudragit L100 AAPS PharmSciTech 10 2009 120 128
42. T. Watanabe, N. Wakiyama, F. Usui, M. Ikeda, T. Isobe, and M. Senna Stability of amorphous indomethacin compounded with silica Int. J. Pharm. 226 2001 81 91 (Pubitemid 32800785)
43. P. Gao, and W. Morozowich Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs Expert Opin. Drug Deliv. 3 2006 97 110 (Pubitemid 43056394)
44. P. Gao, M.E. Guyton, T. Huang, J.M. Bauer, K.J. Stefanski, and Q. Lu Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations Drug Dev. Ind. Pharm. 30 2004 221 229 (Pubitemid 38420267)